Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus

OBJECTIVE: Sympathetic nervous system (SNS) overactivity is a risk factor for insulin resistance and cardiovascular disease (CVD). We evaluated the impact of bromocriptine‐QR, a dopamine‐agonist antidiabetes medication, on elevated resting heart rate (RHR) (a marker of SNS overactivity in metabolic...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Endocrinol Diabetes Metab
Asıl Yazarlar: Chamarthi, Bindu, Vinik, Aaron, Ezrokhi, Michael, Cincotta, Anthony H.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6947713/
https://ncbi.nlm.nih.gov/pubmed/31922028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/edm2.101
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller